By Meaghan Lee Callaghan and Marie Rosenthal
Another Janus kinase (JAK) inhibitor appears effective in reducing death and respiratory failure in patients hospitalized with COVID-19 pneumonia.
STOP-COVID, a double-blind, placebo-controlled study, evaluated the safety and efficacy of tofacitinib (Xeljanz, Pfizer) in 289 hospitalized adults with COVID-19 pneumonia who were not receiving ventilation.
Patients from 15 hospitals in Brazil were randomly assigned to receive either tofacitinib 10 mg twice